Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Shares Set to Reverse Split on Friday, July 31st

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI)’s stock is going to reverse split before the market opens on Friday, July 31st. The 1-16 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, July 30th.

Calidi Biotherapeutics Trading Up 6.1%

Shares of CLDI opened at $0.11 on Thursday. The firm has a market cap of $2.04 million, a price-to-earnings ratio of -0.02 and a beta of 1.30. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.92 and a current ratio of 1.92. Calidi Biotherapeutics has a fifty-two week low of $0.10 and a fifty-two week high of $10.92. The firm has a 50 day moving average price of $0.16 and a 200-day moving average price of $0.44.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. DRW Securities LLC purchased a new position in shares of Calidi Biotherapeutics in the fourth quarter worth about $173,000. Geode Capital Management LLC lifted its stake in shares of Calidi Biotherapeutics by 41.7% in the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after acquiring an additional 12,334 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Calidi Biotherapeutics during the 4th quarter valued at about $25,000. 12.53% of the stock is owned by institutional investors.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.